StockData
Edwards Lifesciences Corp logo

Edwards Lifesciences Corp (EW) stock

EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3062% above fair value
$105.43−1.68 (-1.57%)

Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –

Edwards Lifesciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Edwards Lifesciences's operating cash flow for the twelve months ending Jun 30, 2026 was $1.72B, up 116.4% year over year. For fiscal 2025 it was $1.60B, up 194.2% from the year before. Over ten years it grew 11.2% a year on average. The highest annual figure on record is $1.73B in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.60B+194.2%
FY2024Dec 31, 2024$542.30M-39.5%
FY2023Dec 31, 2023$895.80M-26.5%
FY2022Dec 31, 2022$1.22B-29.7%
FY2021Dec 31, 2021$1.73B+64.3%
FY2020Dec 31, 2020$1.05B-10.9%
FY2019Dec 31, 2019$1.18B+27.6%
FY2018Dec 31, 2018$926.70M-7.4%
FY2017Dec 31, 2017$1.00B+42.1%
FY2016Dec 31, 2016$704.40M+28.1%
FY2015Dec 31, 2015$549.70M-46.2%
FY2014Dec 31, 2014$1.02B+116.3%
FY2013Dec 31, 2013$472.70M+30.5%
FY2012Dec 31, 2012$362.10M+17.5%
FY2011Dec 31, 2011$308.20M+22.6%
FY2010Dec 31, 2010$251.40M+52.1%
FY2009Dec 31, 2009$165.30M+7.9%
FY2008Dec 31, 2008$153.20M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$651.90M+124.6%
Q1 FY2026Mar 31, 2026$43.80M-84.4%
Q4 FY2025Dec 31, 2025$450.90M–
Q3 FY2025Sep 30, 2025$573.70M+63.1%
Q2 FY2025Jun 30, 2025$290.20M-21.9%
Q1 FY2025Mar 31, 2025$280.40M–
Q4 FY2024Dec 31, 2024-$127.50M-193.3%
Q3 FY2024Sep 30, 2024$351.80M-14.5%
Q2 FY2024Jun 30, 2024$371.50M+1005.7%
Q1 FY2024Mar 31, 2024-$53.50M-117.0%
Q4 FY2023Dec 31, 2023$136.60M-51.7%
Q3 FY2023Sep 30, 2023$411.50M+32.8%
Q2 FY2023Jun 30, 2023$33.60M-89.9%
Q1 FY2023Mar 31, 2023$314.10M+7.1%
Q4 FY2022Dec 31, 2022$282.80M-24.3%
Q3 FY2022Sep 30, 2022$309.90M-41.7%
Q2 FY2022Jun 30, 2022$332.20M-36.9%
Q1 FY2022Mar 31, 2022$293.30M-2.4%
Q4 FY2021Dec 31, 2021$373.60M-6.6%
Q3 FY2021Sep 30, 2021$531.90M+146.1%
Q2 FY2021Jun 30, 2021$526.10M+127.5%
Q1 FY2021Mar 31, 2021$300.50M+45.1%
Q4 FY2020Dec 31, 2020$399.80M-0.8%
Q3 FY2020Sep 30, 2020$216.10M-50.6%
Q2 FY2020Jun 30, 2020$231.30M-32.2%
Q1 FY2020Mar 31, 2020$207.10M+13706.7%
Q4 FY2019Dec 31, 2019$402.90M+37.6%
Q3 FY2019Sep 30, 2019$437.30M+27.8%
Q2 FY2019Jun 30, 2019$341.20M+143.4%
Q1 FY2019Mar 31, 2019$1.50M-99.0%
Q4 FY2018Dec 31, 2018$292.90M-19.5%
Q3 FY2018Sep 30, 2018$342.30M+10.1%
Q2 FY2018Jun 30, 2018$140.20M-29.1%
Q1 FY2018Mar 31, 2018$151.30M+17.9%
Q4 FY2017Dec 31, 2017$363.90M+81.0%
Q3 FY2017Sep 30, 2017$310.80M+50.9%
Q2 FY2017Jun 30, 2017$197.70M–
Q1 FY2017Mar 31, 2017$128.30M–
Q4 FY2016Dec 31, 2016$201.10M–
Q3 FY2016Sep 30, 2016$205.90M–

More Edwards Lifesciences figures

See a number that looks wrong?